Skip to content

Intervention Study on Psychocardiology by Xinkeshu tablets

Intervention Study on Psychocardiology by Xinkeshu tablets

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17010940
Enrollment
Unknown
Registered
2017-03-21
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

1:Xinkeshu

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed "psychocardiology" patients; 2. Aged 18 to 85 years old; 3. Chinese medicine syndrome for qi stagnation blood stasis (and certificate includes: phlegm syndrome, deficiency syndrome); 4. Participate in this study voluntarily and have signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Chest pain caused by the stomach, neck sympathetic ganglia compression; (2) Combined with atrial fibrillation, rapid arrhythmia; (3) EF <30% by echocardiography; (4) Severe liver, kidney, nerve, coagulation dysfunction; (5) Pregnant or lactating women; (6) Suspected aortic dissection; (7) During the test can not stop the anti-angina drug application; (8) Previously diagnosed psychiatric patients, including bipolar disorder, manicure depression psychosis, schizophrenia, suicidal tendencies of patients; (9) Previously allergy to this study drug ingredients.

Design outcomes

Primary

MeasureTime frame
The onset of chest pain degree and frequency;the degree of Anxiety and depression;telomerase length of Peripheral blood;metabonomics;

Countries

China

Contacts

Public ContactMinzhou Zhang

Guangdong Provincial Hospital of Traditional Chinese Medicine

mina0511@hotmail.com+86 020-81887233-32802

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 4, 2026